<unk>  is a part of TORCH group of infections caused by protozoan parasite, Toxoplasma gondii. In United States 89% of women in the childbearing age are susceptible to have an acute infection and are at risk for transmitting the parasite to the baby, if an acute infection occurs during the gestational period. Motile tachyzoites cross the placenta, and the frequency their transmission via the placenta is inversely related to the period of gestation. The severity of the disease is dependent on the timing of infection during the gestational period--earlier the infection more severe the disease. Infection in the first trimester results in miscarriage, still born or new born with severe neurological deficits. Newborns with infection acquired later in the pregnancy are asymptomatic at birth but develop neurological manifestations in the first or second decade. Prenatal screening and establishment of the timing of infection using serological tests plays a key role in the management of<unk> . Amniotic fluid PCR is useful to confirm the infection in the fetus. Medical therapy for acute infection in the mother with no fetal infection,  spiramycin throughout the pregnancy is recommended. In pregnant women with a confirmed fetal infection pyrimethamine, sulfadiazine and leucovorin is recommended. Education on  prevention of T.gondii infection is recommended to all pregnant women to minimize the risk of infection.
Congenital Toxoplasmosis
Congenital CMV
Congenital syphilis
Congenital rubella syndrome
Neonatal herpes simplex
Neonatal malaria
Neonatal lupus erythematosus
Neonatal tetanus